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ABSTRACT Apolipoprotein E- (apoE) deficient (E2y2)
mice develop severe hyperlipidemia and diffuse atherosclero-
sis. Low-dose expression of a human apoE3 transgene in
macrophages of apoE-deficient mice (E2y2hTgE1y0), which
results in about 5% of wild-type apoE plasma levels, did not
correct hyperlipidemia but significantly reduced the extent of
atherosclerotic lesions. To investigate the contribution of
apoE to reverse cholesterol transport, we compared plasmas
of wild-type (E1y1), E2y2, and E2y2hTgE1y0 mice for the
appearance of apoE-containing lipoproteins by electrophore-
sis and their capacity to take up and esterify 3H-labeled
cholesterol from radiolabeled fibroblasts or J774 macro-
phages. Wild-type plasma displayed lipoproteins containing
apoE that were the size of high density lipoprotein and that
had either electrophoretic a or g mobilities. Similar particles
were also present in E2y2hTgE1y0 plasma. Depending on
incubation time, E2y2 plasma released 48–74% less 3H-
labeled cholesterol from fibroblasts than E1y1 plasma,
whereas cholesterol eff lux into E2y2hTgE1y0 plasma was only
11–25% lower than into E1y1 plasma. E2y2hTgE1y0 plasma
also released 10% more 3H-labeled cholesterol from radiola-
beled J774 macrophages than E2y2 plasma. E1y1 and E2y
2hTgE1y0 plasma each esterified significantly more cell-
derived 3H-labeled cholesterol than E2y2 plasma. Moreover,
E2y2 plasma accumulated much smaller proportions of fi-
broblast-derived 3H-labeled cholesterol in fractions with elec-
trophoretic g and a mobility than E1y1 and E2y2hTgE1y0
plasma. Thus, low-dose expression of apoE in macrophages
nearly restored the cholesterol eff lux capacity of apoE-
deficient plasma through the formation of apoE-containing
particles, which efficiently take up cell-derived cholesterol,
and through the increase of cholesterol esterification activity.
Thus, macrophage-derived apoE may protect against athero-
sclerosis by increasing cholesterol eff lux from arterial wall
cells.
Apolipoprotein E (apoE) plays a pivotal role in transport of
plasma lipids. Predominantly synthesized by the liver, apoE is
a structural component of chylomicron remnants, very low
density lipoproteins, intermediate density lipoproteins, and
some subpopulations of high density lipoproteins (HDLs)
(1–3). As a ligand of at least two hepatic apoE receptors, apoE
mediates the removal of cholesterol-rich lipoproteins from the
circulation (4). ApoE deficiency in both humans and mice
results in massive remnant hyperlipidemia and early onset of
diffuse atherosclerosis (5–9).
Macrophages also produce apoE, although to a much lesser
extent than hepatocytes, and contribute significantly to the
initiation and progression of atherosclerosis (reviewed in 10,
11). In fact, atherosclerosis can be inhibited by transplantation
of bone marrow, which contains stem cells for macrophage
generation, from apoE-producing mice into apoE-deficient
mice and by selective expression of a human apoE transgene
in macrophages of apoE-deficient mice (12–14). Conversely,
implantation of bone marrow from apoE-deficient mice pro-
motes atherosclerosis in wild-type mice (15). Since neither
expression of a human apoE transgene in macrophages of
apoE-deficient mice nor transplantation of apoE-deficient
macrophage stem cells into wild-type mice causes significant
changes in plasma lipid levels (14, 15), antiatherogenic effects
of macrophage-derived apoE appears to be independent of
hypolipidemic effects.
One possible explanation for the antiatherogenicity of mac-
rophage-derived apoE is its contribution to cholesterol eff lux
and reverse cholesterol transport (1, 2, 10, 11). In vitro, lipid
loading of macrophages stimulates the synthesis and secretion
of apoE, a process that facilitates cholesterol eff lux from these
cells (16–22). Moreover, we and Krimbou et al. have demon-
strated in human and murine plasmas a lipoprotein that
contains apoE (g-LpE) as its only protein constituent and that
releases cholesterol from cells (2, 3, 23–25).
To investigate further the contribution of macrophage-
derived apoE to reverse cholesterol transport, we compared
the cholesterol eff lux capacities of plasmas from wild-type
mice, completely apoE-deficient mice (E2y2), and from apoE-
deficient mice hemizygous for expression of a human apoE3
transgene in macrophages (E2y2hTgE1y0). Because the met-
abolic fate of macrophage-derived apoE is unknown, we also
investigated the appearance of apoE-containing lipoproteins
on electrophoretic gels and their ability to take up radiolabeled
cholesterol from cells.
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MATERIALS AND METHODS
Animals and Sample Acquisition. Wild-type C57BLy6J
mice (E1y1) were purchased from Harlan (Borchen, Germa-
ny). E2y2 and E2y2hTgE1y0 mice were described previously (8,
14, 26). E2y2 mice were originally generated in C57BLy6J 3
129yJ hybrids by gene targeting. Two pairs of mice were
provided by Nobuyo Maeda (University of North Carolina,
Chapel Hill, NC) and used for breeding. Selective expression
of human apoE in macrophages was achieved by transgenic
expression of an apoE3 gene construct containing the sheep
visna virus long terminal repeat. Transgenic mice homozygous
for this gene construct were crossed with E2y2 mice to obtain
E1y2hTgE1y0 mice. The E1y2hTgE1y0 progeny was then bred
back to the E2y2 mice to obtain the E2y2hTgE1y0 mice which
were the subject of this study. The genotype of the mice was
assessed by Southern blotting, and the lipid profiles and
amounts of atherosclerosis were analyzed (14). Subsequently
the E2y2hTgE1y0 mice were bred with E2y2 mice to obtain a
more homogeneous genetic background.
The experiments described here were performed in six
independent series. Mice were fed a regular chow diet (4RF21,
Mucedola, Milan, Italy). E2y2 and E2y2hTgE1y0 mice were
selected on the basis of similar levels of total plasma choles-
terol (Table 1). At 14–16 weeks of age, nonfasting mice were
anesthetized and blood was collected by cardiac or aortic
puncture. Streptokinase was used as the anticoagulant (final
concentration 1000 unitsyml). Plasma samples were obtained
by centrifugation (2000 rpm, 15 min, 4°C). In each series of
experiments plasma samples from three to six mice with
identical genotypes were pooled to produce several aliquots of
500 ml. The aliquots were encoded and kept at 280°C until
analyzed. The experiments were performed on blinded sam-
ples, and the code was broken after analysis of the data.
Quantification of Lipids, Protein, and Apolipoproteins.
Plasma concentrations of cholesterol and triglycerides were
measured enzymatically with kits from Boehringer Mannheim.
The plasma concentration of human apoE was determined by
sandwich enzyme immuoassay (24).
Demonstration of Lipoproteins by Agarose Gel Electro-
phoresis and Nondenaturing Two-Dimensional Electrophore-
sis. Aliquots of plasma (1 ml) were fractionated by electro-
phoresis in precast agarose gels (Ciba Corning). Lipoproteins
were stained for neutral lipids by Fat Red 7B according to the
manufacturer9s instructions. Alternatively, proteins were elec-
troblotted onto nitrocellulose membranes so that the lipopro-
teins could be detected by their apolipoprotein content. To
detect apoA-I- and apoB-containing lipoproteins, the mem-
branes were incubated with sheep antibodies against human
apoA-I or apoB (Boehringer Mannheim). Antigen–antibody
complexes were then detected with a rabbit anti-sheep IgG
antiserum conjugated to horseradish peroxidase (Dako) and
with 4-chloronaphthol as the chromogen. To detect apoE-
containing lipoproteins, we used IgG of either a sheep anti-
serum against human apoE (WAK Chemie, Bad Homburg,
Germany) or a rabbit antiserum against mouse apoE (kindly
provided by Yadong Huang, Gladstone Institute of Cardio-
vascular Disease, San Francisco, CA). To avoid cross-reactions
of secondary antibodies with mouse IgG, which would have
interfered with the detection of g-LpE (23–25), we biotin-
ylated anti-apoE antibodies as recommended by the manufac-
turer of the protein biotinylation kit (Sigma). The apoE–
antibody complexes were visualized with a streptavidin-bio-
tinylated horseradish peroxidase complex (Amersham) and a
chemiluminescent blotting substrate (Boehringer Mannheim).
The chemiluminescence reaction was recorded by photoimag-
ing with the BAS1500 (Fuji, Japan).
ApoE-containing lipoproteins were also demonstrated by
nondenaturing two-dimensional polyacrylamide gradient gel
electrophoresis (2D-PAGGE) of mouse plasma followed by
anti-apoE immunoblotting, principally as described previously
(23–25). Briefly, in the first dimension, 40 ml of plasma was
separated by electrophoresis at 4°C in a 0.75% agarose gel.
Agarose gel strips containing the separated lipoproteins were
then transferred to a 3–20% polyacrylamide gradient gel.
Separation in the second dimension was performed at 40 mA
at 10°C. The proteins separated in the PAGGE gel were
electroblotted onto a nitrocellulose membrane. ApoE-
containing lipoproteins were detected with biotinylated anti-
bodies against either human apoE or mouse apoE as described
above.
Determination of 3H-Labeled Cholesterol Eff lux from Cul-
tured Cells into Mouse Plasma or Lipoproteins. Normal
human skin fibroblasts (3 3 105; 5–10 passages old) from two
donors were cultured in DMEM containing 10% fetal calf
serum in either 3.5-cm dishes or in 2.5-cm wells of 12-well
plates. Alternatively, 4 3 105 J774 macrophages were culti-
vated in 3.5-cm dishes. At about 70–80% confluence, cells
were labeled in the presence of fetal calf serum with 0.5 mCi
(for fibroblasts in 3.5-cm dishes) or 0.1 mCi (for fibroblasts in
2.5-cm wells or J774 macrophages in 3.5-cm dishes) [1,2-3H]-
cholesterol (51.7 Ciymmol, New England Nuclear) for 72 h at
37°C. After six washes with PBS (pH 7.4), the specific radio-
activity was 5.0 6 1.2 3 106 cpmymg protein (fibroblasts) or
1.2 6 0.2 3 106 cpmymg protein (J774 cells).
To measure cholesterol eff lux capacity and esterification
activity of total plasma, radiolabeled fibroblasts in 2.5-cm
wells were incubated for 1 min or for 1 h with plasma diluted
in DMEM to a final concentration of 4% (vol:vol) (25).
Radiolabeled J774 macrophages were incubated with 4%
plasma for either 1 min or 1, 2, 4, 8, or 12 h. After incubation,
the medium was removed, and cell debris was pelleted by
centrifugation at 30,000 rpm for 15 min at 4°C. After removal
of the supernatant radioactivity in a 50-ml aliquot was
determined directly by scintillation spectrometry. Lipids
from a 375-ml aliquot were extracted with chloroform-
:methanol (2:1, vol:vol) for 72 h, and unesterified cholesterol
(UC) and cholesteryl esters (CEs) were separated by TLC in
silica gel plates (Merck, Darmstadt, Germany) using hex-
ane:ether (6:4, vol:vol) as the mobile phase. Cells were lysed
with 1.5 ml of 0.5 M NaOH, and their lipids were extracted
with hexane:isopropanol (3:2, vol:vol). The associated ra-
dioactivity was counted by scintillation spectrometry. Frac-
tional cholesterol eff lux was calculated as cpmmediumy
(cpmmedium 1 cpmcells) 3 100%. Fractional esterification rate
was calculated as cpmCEy(cpmCE 1 cpmUC) 3 100%.
To measure the uptake of cell-derived 3H-labeled UC into
lipoprotein subfractions, radiolabeled fibroblasts of 3.5-cm
dishes were incubated for 1 min with 0.5 ml of mouse plasma
(2, 23–25). After incubation, the medium was removed, and
cell debris was sedimented by centrifugation (30,000 rpm, 15
min, 4°C). Thereafter, 40-ml aliquots of plasma were separated
by agarose gel electrophoresis under the conditions described
above for 2D-PAGGE (2, 23–25). Each gel lane was cut into
0.5-cm segments and transferred to a vial containing 5 ml of
scintillation buffer (Instant Scint Gel PL, Packard Instruments
BV, Groningen, The Netherlands). This buffer completely
solubilized the agarose gel so that the radioactivity of 3H-
labeled cholesterol could be measured directly.
Alternatively, radiolabeled and nonradiolabeled aliquots of
an identical specimen were separated in parallel by 2D-
PAGGE as described above. After separation, the half of the
Table 1. Effect of genotype on plasma lipid levels (mgydl)
Wild type E2y2 E2y2hTgE1y0
Cholesterol 83 6 31 450 6 93 405 6 71
Triglycerides 72 6 40 215 6 71 243 6 52
Lipid levels for each genotype were measured in five pools of plasma
from three to four mice each. Values are mean 6 SD.
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PAGGE gel with the radiolabeled sample was stored at 4°C.
The other half of the gel with the nonradiolabeled sample was
electroblotted onto a nitrocellulose membrane to identify
apoE-containing lipoproteins. The immunoblot was then used
as a template to localize the corresponding lipoproteins in the
radiolabeled half of the gel. The gel slices containing these
lipoproteins were cut out and incubated with chloroform-
:methanol (2:1, vol:vol) for 72 h to extract their lipids. After
evaporation of the organic solvent, lipids were solubilized in 5
ml of scintillation buffer and the radioactivity was measured by
scintillation spectrometry (23–25).
Statistical Analysis. Because of the considerable interassay
variation in cholesterol eff lux experiments (27), some results
were expressed as percentages of the results obtained with
E2y2 plasma. The statistical significance of differences in
fractional cholesterol eff lux capacities and cholesterol esteri-
fication rates among the various plasmas was determined by t
tests or ANOVA as indicated. All calculations were done with
the Statistical Package for the Social Sciences. Data are
reported as the mean 6 SD.
RESULTS
Effect of Macrophage ApoE on Plasma Levels of Lipids,
Lipoproteins, and ApoE. As reported previously (8, 9, 14),
E2y2 and E2y2hTgE1y0 mice had severe mixed hyperlipidemia
(Table 1) which was associated with an accumulation of
remnant lipoproteins and a decrease in the concentration of
HDL (not shown, see ref. 14), the predominant lipoprotein
class in wild-type mice. The plasma concentration of human
apoE in E2y2hTgE1y0 mice was 1.5–4.4 mgyml. This level is
less than 7% and 10% of the serum apoE levels in wild-type
mice and humans, respectively (14, 24, 28). Neither the cho-
lesterol and triglyceride concentrations nor lipoprotein pro-
files of plasma differed significantly between the E2y2 and
E2y2hTgE1y0 mice.
Electrophoretic Appearance of Lipoproteins. To investigate
the effects of macrophage-derived apoE on the distribution of
apolipoproteins among lipoproteins, plasma from each mouse
strain was separated by agarose gel electrophoresis (Fig. 1). As
expected, lipid staining of the gel identified the majority of
lipoproteins in plasma of wild-type mice with electrophoretic
a mobility and only a minority with b mobility. The a-migrat-
ing lipoprotein contained most of the anti-apoA-I and anti-
apoE immunoreactive material. Minor proportions of apoA-I
and apoE were found in pre-b-migrating fractions. Small
proportions of apoE were also detected in a g-migrating
fraction. It is noteworthy that mouse apoE was detected by
antibodies against either mouse apoE or human apoE (Figs.
1D and 1E, respectively). ApoB was detected in two bands that
had b- and pre-b mobilities (Fig. 1C). In both types of
apoE-deficient plasma, the majority of lipoproteins migrated
as a broad b-band (Fig. 1 A) which reacted with anti-apoA-I-
and anti-apoB- antibodies (Fig. 1 B and C). Only a small
proportion of apoA-I was found in a fraction with a mobility.
Expression of apoE in macrophages did not change the
electrophoretic appearance of apoA-I and apoB-containing
lipoproteins. As in normal mouse plasma, the vast majority of
human apoE in E2y2hTgE1y0 plasma was immunodetected in
an a-migrating fraction and a minority in g- and pre-b-
migrating fractions (Fig. 1E).
To further differentiate apoE-containing lipoproteins,
plasma was separated by 2D-PAGGE. In E1y1 plasma, anti-
apoE immunoblotting identified apoE-containing particles
with g mobility (i.e., g-LpE), pre-b mobility (i.e., pre-b-LpE),
and a mobility (i.e., a-LpE) (Fig. 2A). The latter two were
inhomogenous with respect to size and staining intensity and
hence appeared to consist of heterogenous particles. As ex-
pected, no apoE-containing particles were found in E2y2
plasma (Fig. 2B). However, particles with the electrophoretic
properties of g-LpE, pre-b-LpE, and a-LpE were immunode-
tectable in plasma of E2y2hTgE1y0 mice (Fig. 2C).
Effect of Macrophage-Derived ApoE on Cholesterol Eff lux
and Cholesterol Esterification Capacities of Mouse Plasma.
Depending on incubation time, E1y1 plasma released 48% (1
h) to 74% (1 min) more 3H-labeled cholesterol from fibroblasts
than E2y2 plasmas (Table 2) Compared with E2y2 plasma,
macrophage-specific expression of apoE in E2y2hTgE1y0 mice
increased cholesterol eff lux capacity by 37% (1 h) to 49% (1
min) (Table 2, both P , 0.001, t test). As a consequence,
cholesterol eff lux from fibroblasts into E2y2 plasma was only
11% (1 h) to 25% (1 min) lower than that of E1y1 mouse
plasma (not significant, Table 2).
Cholesterol eff lux from J774 macrophages during 1-min
incubation with plasmas from E1y1, E2y2, and E2y2hTgE1y0
mice did not differ significantly. Paradoxically, 1 h and longer
FIG. 1. Electrophoretic demonstration of lipoproteins in plasmas
of wild-type, E2y2, and E2y2hTgE1y0 mice. Aliquots (1 ml) of plasma
were separated by electrophoresis in agarose gels. Lipoproteins were
then demonstrated by staining with Fat Red 7B (A) or by immuno-
blotting with antibodies against human apoA-I (B), human apoB (C),
murine apoE (D), or human apoE (E). Lane 1 contains E1y1 plasma;
lane 2, E2y2 plasma, and lane 3, E2y2hTgE1y0 plasma. Anti-human
apoE antibodies cross-react with mouse apoE, whereas anti-mouse
apoE antibodies do not cross-react with human apoE. In both E2y2
(lane 2) and E2y2hTgE1y0 plasma (lane 3), broad b-migrating rem-
nants immunoreacted with anti-apoA-I and anti-apoB antibodies (B
and C) but not with anti-apoE antibodies. In
E2y2hTgE1y0 plasma, apoE was present in lipoproteins that have
electrophoretic a, pre-b, or g mobility.
FIG. 2. Nondenaturing 2D-PAGGE of apoE-containing lipopro-
teins in plasma from E1y1 (A), E2y2 (B), and E2y2hTgE1y0 mice (C).
For nondenaturing 2D-PAGGE agarose gel electrophoresis was fol-
lowed by nondenaturing polyacrylamide gradient gel electrophoresis.
After electroblotting to nitrocellulose membranes, apoE-containing
lipoproteins were detected with biotinylated antibodies against either
murine (A and B) or human apoE (C) and streptavidin-horseradish
peroxidase. The boxes indicate the position of the various particles and
also the regions that were removed in the cholesterol eff lux experi-
ments depicted in Fig. 5.
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incubations of normolipidemic plasmas from wild-type mice
with J774 macrophages led to significantly less cholesterol
eff lux than incubations with hyperlipidemic plasmas of E2y2
or E2y2hTgE1y0 mice. Cholesterol eff lux from J774 macro-
phages into E2y2hTgE1y0 plasma was consistently higher
(mean 11%, range 5–20%) higher than into E2y2 plasma
during incubations of 1–12 h (P , 0.0001 for the entire curve
as tested by ANOVA; P , 0.01 for 1-h and 4-h incubations as
tested by t test) (Fig. 3A).
During a 1-h incubation with radiolabeled fibroblasts, E2y2
plasma esterified significantly 47% and 39% less cell-derived
3H-labeled UC than plasma from wild-type or E2y2hTgE1y0
mice, respectively (Table 2). The difference between E1y1 and
E2y2hTgE1y0 plasma (mean 23%) was not statistically signif-
icant. After 1- to 12-h incubations, 7–25% more cholesterol
derived from J774 macrophages was esterified by E2y2
hTgE1y0 plasma than by E2y2 plasma (P 5 0.005 for the entire
curve as tested by ANOVA; P , 0.01 for the 4-h incubation as
tested by t test) (Fig. 3B).
Effect of Macrophage-Derived ApoE on the Uptake of
Cell-Derived Cholesterol by Lipoproteins. To identify the
lipoproteins responsible for the defective uptake of cell-
derived 3H-labeled cholesterol by E2y2 plasma and for the
reversal of this defect in E2y2hTgE1y0 plasma, plasmas were
incubated for 1 min with 3H-cholesterol-labeled fibroblasts and
then separated by agarose gel electrophoresis (Fig. 4) or
2D-PAGGE (Fig. 5). The g- and a-fractions of E2y2 plasma
contained significantly less radioactivity than those from E1y1
or E2y2hTgE1y0 plasma. Compared with E1y1 plasma,
E2y2hTgE1y0 plasma took up a significantly greater propor-
tion by its g-migrating fraction (Fig. 4). Uptake of cell-derived
3H-labeled cholesterol by the various lipoproteins was also
analyzed by 2D-PAGGE to remove background radioactivity
in the g-fraction (likely from residual cell debris) and to
quantify the uptake of cell-derived 3H-labeled cholesterol by
the small pre-b-migrating apoE particle (see Fig. 2) which also
was otherwise contaminated with background radioactivity
(from pre-b-migrating remnants) (see Figs. 1 and 4). g-LpE,
pre-b-LpE, and a-LpE fractions of E1y1 and E2y2hTgE1y0
plasmas did not contain significantly different pools of radio-
labeled cholesterol in the medium (Fig. 5). Compared with
E2y2 plasma, E1y1 and E2y2hTgE1y0 plasmas contained five
to eight times more cell-derived 3H-labeled cholesterol in the
g-LpE, pre-b-LpE, and a-LpE fractions (Fig. 5).
DISCUSSION
Several animal studies have pointed to an anti-atherogenic role
of macrophage-derived apoE which is independent of the
hypolipidemic effects of apoE (see Introduction and refs. 10,
11, 14, 15, 29). Because of apoE’s presence in certain HDL
subclasses that release cholesterol from cells, several investi-
gators have hypothesized that its antiatherogenic effects derive
from its contribution to the reverse transport of excess cho-
lesterol from arterial wall cells to the liver (1, 2, 10, 11, 16–25).
To test this hypothesis, we compared plasma from wild-type
mice (E1y1), apoE-deficient mice (E2y2), and apoE-deficient
mice expressing human apoE expression in macrophages
(E2y2hTgE1y0) for lipoprotein composition and for the ability
FIG. 3. Cholesterol eff lux from murine J774 macrophages (A) and
esterification of cell-derived cholesterol (B) by plasma from E2y2 and
E2y2hTgE1y0 mice. Diluted (4%) mouse plasma was incubated for
increasing times with 3H-cholesterol-labeled J774 macrophages. To
determine cholesterol eff lux capacity, radioactivity in the medium was
measured directly, and radioactivity in the cells was measured after
lysis of cells with NaOH and lipid extraction. The fractional cholesterol
eff lux rate was calculated as cpmmediumy(cpmmedium 1 cpmcells) 3
100% (A). To determine the esterification activity, lipids were ex-
tracted from the medium and separated by TLC to measure the
radioactivity of UC and CE, and the fractional esterification rate was
calculated as cpmCEy(cpmCE 1 cpmUC) 3 100% (B). Symbols and
bars represent mean values and SDs of a triplicate cholesterol eff lux
experiment (A) and a quintuplicate esterification experiment (B).
Statistical analysis of pooled data by ANOVA showed that both the
cholesterol eff lux (P , 0.0001) and cholesterol esterification capacities
(P 5 0.005) of E2y2 and transgenic E2y2hTgE1y0 mouse plasmas
differed significantly. In addition symbols (#) indicate specific time
points at which the cholesterol eff lux and esterification capacities of
E2y2 and E2y2hTgE1y0 mice differed significantly upon t test (P ,
0.01).
Table 2. Effect of genotype on cholesterol eff lux and esterification capacities of murine plasmas
E1y1
(N57)
E2y2
(N512)
E2y2hTgE1y0
(N57)
E1y1 vs.
E2y2
E2y2 vs.
E2y2hTgE1y0
E1y1 vs.
E2y2hTgE1y0
Cholesterol eff lux (1-min incubation) 174 6 43 100 6 10 149 6 20 ,0.001 0.008 0.231
Cholesterol eff lux (1-h incubation) 148 6 15 100 6 8 137 6 18 ,0.001 0.004 0.244
Cholesterol esterification (1-h incubation) 187 6 42 100 6 7 164 6 26 ,0.001 ,0.001 0.143
Plasma from several mice per genotype were pooled. In every indicated series of experiments, 4% dilutions of these plasmas were incubated for
either 1 min or 1 h with [3H]cholesterol-labeled fibroblasts. Lipids were extracted from both the medium and the cells to count the radioactivity
to calculate fractional cholesterol eff lux rates by cpm mediumy(cpmmedium1cpmcells) 3 100%. Lipids of the medium were also separated by TLC to
separate UC and CE and to calculate the fractional esterification rate by cpmCEy(cpmCE 1 cpmUC) 3 100%. N gives the number of experiments
per sample. Data were obtained from four independent series of experiments. Because of the high interassay variation, the data of all series were
summarized as percentage of the fractional eff lux or esterification rates which were obtained with E2y2 plasma in the respective series. P values
for genotype-related differences were calculated using an unpaired t test.
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to release 3H-labeled cholesterol from radiolabeled fibroblasts
and J774 macrophages.
The small amounts of apoE in plasma of E2y2hTgE1y0 mice
were predominantly found in particles with electrophoretic a
mobility and, to a lesser extent, in particles with either g or
pre-b mobility. By size, these particles correspond to HDL.
Cholesterol eff lux from fibroblasts into E2y2 plasma was
48–74% lower than into wild-type plasma. Although produc-
ing less than 7% of the apoE levels in wild-type plasma (14, 28),
expression of human apoE in macrophages of E2y2hTgE1y0
mice nearly corrected this eff lux deficit. Cholesterol eff lux
from J774 macrophages into E2y2hTgE1y0 plasma was also
significantly higher than into E2y2 plasma. However, the
difference in cholesterol eff lux capacities of E2y2 and
E2y2hTgE1y0 plasmas was smaller in the presence of J774
macrophages than in the presence of fibroblasts (Table 2 and
Fig. 3A).
The cholesterol eff lux capacity of total plasma results from
complex interactions between several components in plasma
and cells (reviewed in refs. 11, 30, 31). Thus, incubation of
radiolabeled cells with unlabeled plasma leads to an unspecific
exchange of isotopic cholesterol molecules in cell membranes
and nonisotopic cholesterol molecules in lipoproteins. Ester-
ification of cholesterol by lecithin:cholesterol acyltransferase
(LCAT) in lipid-rich, a-migrating HDL modifies this unpro-
ductive bidirectional equilibration process into slow and un-
saturable net cholesterol eff lux (32–34). Accordingly, regres-
sion analyses have identified levels of HDL cholesterol,
apoA-I, and LCAT activity as important determinants of
plasma cholesterol eff lux capacity (27). In addition, lipid-free
apolipoproteins and lipid-poor HDL subclasses, such as pre-
b-migrating HDL, promote fast, saturable, and LCAT-
independent cholesterol eff lux (31, 32, 35–39).
The relative contributions of the two different types depend
on the kind of cells used in efflux experiments (31–39). From
studies of reverse cholesterol transport in plasma from patients
with apoA-I deficiency or subjects with different apoE phe-
notypes and in plasma from apoA-I- or apoE-deficient mice,
we have concluded that apoE is another important determi-
nant of cholesterol eff lux capacity (2, 23–25, 40). However,
deficiency of either apoA-I or apoE and differences in apoE
phenotype are associated with considerable changes in all
lipoprotein classes, which may affect cholesterol eff lux capac-
ity independently of apoE. Since low-dose expression of apoE
in macrophages of E2y2hTgE1y0 mice did not significantly
alter the lipoprotein profile in apoE-deficient mouse plasma
(14), our present results provide strong evidence that apoE
affects cholesterol eff lux directly rather than indirectly (e.g.,
through modulation of the lipoprotein composition in plasma).
In conjunction with previous work, our studies point to three
mechanisms by which apoE may regulate the ability of plasma
to take up cholesterol from cells.
First, a-migrating HDL with apoE are more potent accep-
tors of cell-derived cholesterol than a-migrating HDL without
apoE. In our experiments, the largest proportion of macro-
phage-derived apoE was associated with a-migrating HDL
(Figs. 1 and 2). The absence of apoE from this fraction in E2y2
plasma was associated with a dramatic decrease in the uptake
of cell-derived 3H-labeled cholesterol from fibroblasts into
a-migrating HDL. The presence of apoE in a-migrating HDL
of E2y2hTgE1y0 mice nearly corrected this deficit (Figs. 4 and
5). These data are in agreement with those reported by Basu
et al. (16, 17) and Hayek et al. (40). These authors showed that
the capacity of apoE-depleted HDL of men or HDL of
apoE-deficient mice to promote cholesterol eff lux from mouse
FIG. 4. Uptake of cell-derived 3H-labeled cholesterol by various
lipoproteins of apoE-plasma from wild-type (A), E2y2 (B), and
E2y2hTgE1y0 (C) mice. Mouse plasma was incubated for 1 min with
3H-cholesterol-labeled normal human fibroblasts. Lipoproteins from
aliquots of plasma (40 ml) were then electrophoresed in 0.75% agarose
gels. After electrophoresis, each lane of the gel was cut into 5-mm
segments. Each segment was dissolved in scintillation buffer, and the
radioactivity was determined by liquid scintillation spectrometry. The
data summarize results of three experiments per genotype and rep-
resent the percentage of radioactivity in the a-, pre-b-, b-, and
g-migrating fractions of the gel. The statistical significance of differ-
ences between E2y2 (p) and wild-type mice (#) was estimated by t test.
p #, P , 0.05; pp, P , 0.01; ppp, P , 0.001.
FIG. 5. Uptake of cell-derived 3H-labeled cholesterol by apoE-
containing lipoproteins in plasma from wild-type E1y1, E2y2, and
E2y2hTgE1y0 mice. Mouse plasma was incubated for 1 min with
3H-cholesterol-labeled normal human fibroblasts. Lipoproteins from
aliquots of plasma (40 ml) were then separated by 2D-PAGGE in
parallel with a nonradiolabeled sample. Anti-apoE-immunoblots of
2D-electropherograms of E1y1 plasma were used to localize lipopro-
teins (see Fig. 3). The area containing the liporoteins were removed
from the native gels, their lipids were extracted, and the radioactivity
was counted. For further details, see Materials and Methods. The bars
represent the percentage of radioactivity in 40 ml of medium released
into the various lipoproteins and reflect mean data of two independent
experiments. The percentages do not add to 100% because some
lipoproteins were not removed from the gel or did not migrate into the
gel (e.g., remnants) and because of incomplete recovery.
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peritoneal macrophages is decreased and can be restored to
normal by the addition of apoE to HDL.
Second, g-LpE is important for the ability of plasma to
promote cholesterol release from cells. In both E1y1 and
E2y2hTgE1y0 plasma there is an apoE-containing lipoprotein
with an electrophoretic mobility resembling that of g-LpE
from human plasma (Figs. 1 and 2) (2, 3, 23, 24). The absence
of this fraction in E2y2 plasma was associated with a signifi-
cantly reduced proportion of cell-derived 3H-labeled choles-
terol taken up by this fraction. We considered g-LpE like
pre-b1-HDL to be an initial and fast acceptor of fibroblast-
derived cholesterol. Thus, it is important to note that choles-
terol eff lux from fibroblasts into E2y2 plasma was reduced to
a greater extent during a 1-min incubation than during a 1-h
incubation (228% versus E2y2hTgE1y0 plasma and 232%
versus E1y1 plasma) (Table 2). The importance of the cell type
for the contribution of fast cholesterol eff lux onto lipid-poor
acceptors (11, 31) is indicated by our observation that in the
presence of J774 macrophages 1-min cholesterol eff lux into
E2y2 plasma and E2y2hTgE1y0 plasma did not differ signifi-
cantly (Fig. 3A).
Third, ApoE increases the esterification of cell-derived
cholesterol by plasma. Compared with apoE-containing
plasma from both E1y1 and E2y2hTgE1y0 mice, E2y2plasma
had 40–45% less ability to esterify fibroblast-derived choles-
terol and 10–25% less ability to esterify J774 macrophage-
derived cholesterol (Table 2 and Fig. 3B). Possible reasons for
this reduction include the lack of apoE as a LCAT activator
(41, 42) and the absence of lipoproteins that are important for
effective cholesterol esterification. In any case, the decreased
ability of E2y2 plasma to esterify cell-derived cholesterol
appears to be causally linked to decreased cholesterol eff lux,
because esterification of cell-derived cholesterol by LCAT is a
prerequisite for net cholesterol eff lux into lipid-rich, mature
HDL such as the a-migrating apoE-containing particle present
in both E1y1 and E2y2hTgE1y0 plasma. Otherwise, the flux of
cholesterol between plasma membranes and lipoproteins
would be bi-directional and unproductive (11, 30–34).
In conclusion, apoE-containing lipoproteins appear to play
an important role in regulating cholesterol eff lux from cells
into plasma. Even low plasma levels of apoE produced by
expression of the apoE gene in macrophages restored to
normal cholesterol eff lux capacity of apoE-deficient plasma.
This may explain why even low-level expression of the human
apoE transgene in apoE-deficient mice inhibits the progression
of atherosclerosis (14).
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